USP2a peptides and antibodies
View Patent ↗The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.
1. A method for staging or monitoring the progression of a disease associated with increased USP2a level in a subject which has said disease, the method comprising:
a) obtaining a sample from the subject;
b) contacting the sample with an anti-USP2a antibody mixture consisting of isolated antibodies that are specifically reactive with a USP2a peptide consisting of the amino acid sequence of SEQ ID NO. 1, or variants thereof, and isolated antibodies that are specifically reactive with a USP2a peptide consisting of the amino acid sequence of SEQ ID NO. 2, or variants thereof;
c) determining a level of USP2a protein in the sample detected by said antibody mixture in an immunoassay; and
d) comparing the level of the USP2a protein in the sample to a positive control baseline level of the USP2a protein, wherein a difference in the level of USP2a protein in the sample as compared to the positive control baseline level of greater than 20% overexpression is indicative of the stage or progression of said disease in the subject.
2. The method of claim 1 , wherein both said isolated antibodies are labeled with a detectable label.
3. The method of claim 2 , wherein the immunoassay for determining the level of USP2a protein is selected from the group consisting of immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunossay (RIA), immunoprecipitation, immunohistochemistry and immunofluorescence.
4. The method of claim 1 , wherein said disease is prostate cancer.
5. The method of claim 1 , wherein the positive control baseline level of USP2a is the level of USP2a protein in a previous sample from said subject.